Use of spiperone derivatives as immunosuppressant agents
US5574041A · kind A · utility
1Cited by
15References
38Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 4, 1992 |
| Grant date | Nov 12, 1996 |
| Priority date | — |
| Expiry date | Jun 4, 2012 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/435
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for suppressing an immune response in a mammal by treating the mammal with an effective amount of spiperone derivative that is without significant neuroleptic effect due to decreased binding to serotonin and/or dopamine receptors as compared with unmodified or uncomplexed spiperone, or due to topical application which maximizes local immunosuppression while limiting systemic absorption and neuroleptic effects. The spiperone derivatives are capable of inhibiting classic contact hypersensitivity reactions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.